Abzena, a contract development and manufacturing organization (CDMO) for complex biologics and bioconjugates, has co-authored a publication with the U.S. FDA demonstrating the potential of the MHC associated peptide proteomics (MAPPs) assay as an important method to interrogate immunogenicity risk and help design superior antibodies and biologics with a higher chance of a successful outcome in patients. The authors highlighted the value of MAPPs in the development of biologics and the precisi...